2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2614

Single Academic Center Experience with 14-3-3 Eta in the Evaluation of Inflammatory Arthritis
Abstract Number: 2615

Changes in a Patient-Reported Measure of Physical Function, PF-10a, Are Most Strongly Associated with Changes in the Patient Global Assessment Portion of a Composite Measure of RA Disease Activity
Abstract Number: 2616

Study of Anti-Carbamylated Protein Antibody in the Rheumatoid Patients Who Were Clinically Active and Under Treatment with Biological Dmards
Abstract Number: 2617

Serum 14-3-3eta Protein Elevation in Osteoarthritis Suggests Misclassification or Concurrent Inflammatory Arthritis
Abstract Number: 2618

Methotrexate Dose May Associated with the Frequency of Lymphoproliferative Disorders in Rheumatoid Arthritis
Abstract Number: 2619

Clinical Usefulness of Periodic Detection of Serum 14-3-3Î· for Predicting Efficacy of Tocilizumab in RA
Abstract Number: 2620

Predictive Value of Anti-Carbamylated Protein Antibodies in Patients with Early Arthritis
Abstract Number: 2621

Characteristics of Histopathology and Clinical Course of 19 Cases That Developed a Lymphoproliferative Disease (LPD) during Methotrexate (MTX) Treatment.
Abstract Number: 2622

Serum RANKL Levels, Associate with Anti Citrullinated Proteins Antibodies (ACPA) in Early-Untreated Rheumatoid Arthritis and Is Modulated Following Methotrexate
Abstract Number: 2623

DAS28-ESR and DAS28-CRP Are Not Exchangeable in Daily Clinical Practice: Data from a Large Outpatient Cohort
Abstract Number: 2624

Preliminary Content Validation of the Patient Reported Outcomes Measurement Information System (PROMIS) Short Forms in People Living with Rheumatoid Arthritis
Abstract Number: 2625

SDAI 50 Is More Stringent Than the EULAR Response Measure and a Better Predictor of Low Disease State/Remission in Early Rheumatoid Arthritis: Results from an Early Arthritis Cohort
Abstract Number: 2626

Disease Activity Predicts ABCB1 and ABCG2 Drug-Efflux Transporters Function in Rheumatoid Arthritis (RA) Patients
Abstract Number: 2627

Does 14-3-3 ETA Protein Offer Any Additional Diagnostic Value in Rheumatoid Arthritis?
Abstract Number: 2628

Identifying Anxiety and Depression Among Rheumatoid Arthritis Patients Using the Multidimensional Health Assessment Questionnaire

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].